These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 17167796)

  • 1. In silico profiling of tyrosine kinases binding specificity and drug resistance using Monte Carlo simulations with the ensembles of protein kinase crystal structures.
    Verkhivker GM
    Biopolymers; 2007 Mar; 85(4):333-48. PubMed ID: 17167796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Computational proteomics of biomolecular interactions in the sequence and structure space of the tyrosine kinome: deciphering the molecular basis of the kinase inhibitors selectivity.
    Verkhivker GM
    Proteins; 2007 Mar; 66(4):912-29. PubMed ID: 17173284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploring sequence-structure relationships in the tyrosine kinome space: functional classification of the binding specificity mechanisms for cancer therapeutics.
    Verkhivker GM
    Bioinformatics; 2007 Aug; 23(15):1919-26. PubMed ID: 17537753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural biology contributions to tyrosine kinase drug discovery.
    Cowan-Jacob SW; Möbitz H; Fabbro D
    Curr Opin Cell Biol; 2009 Apr; 21(2):280-7. PubMed ID: 19208462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imprint of evolutionary conservation and protein structure variation on the binding function of protein tyrosine kinases.
    Verkhivker GM
    Bioinformatics; 2006 Aug; 22(15):1846-54. PubMed ID: 16720585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Important therapeutic targets in chronic myelogenous leukemia.
    Kantarjian HM; Giles F; Quintás-Cardama A; Cortes J
    Clin Cancer Res; 2007 Feb; 13(4):1089-97. PubMed ID: 17317816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Crystal structure of the T315I mutant of AbI kinase.
    Zhou T; Parillon L; Li F; Wang Y; Keats J; Lamore S; Xu Q; Shakespeare W; Dalgarno D; Zhu X
    Chem Biol Drug Des; 2007 Sep; 70(3):171-81. PubMed ID: 17718712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of compound 584, an Abl kinase inhibitor with lasting effects.
    Puttini M; Redaelli S; Moretti L; Brussolo S; Gunby RH; Mologni L; Marchesi E; Cleris L; Donella-Deana A; Drueckes P; Sala E; Lucchini V; Kubbutat M; Formelli F; Zambon A; Scapozza L; Gambacorti-Passerini C
    Haematologica; 2008 May; 93(5):653-61. PubMed ID: 18367480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrating ligand-based and protein-centric virtual screening of kinase inhibitors using ensembles of multiple protein kinase genes and conformations.
    Dixit A; Verkhivker GM
    J Chem Inf Model; 2012 Oct; 52(10):2501-15. PubMed ID: 22992037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Construction and validation of a RET TK catalytic domain by homology modeling.
    Tuccinardi T; Manetti F; Schenone S; Martinelli A; Botta M
    J Chem Inf Model; 2007; 47(2):644-55. PubMed ID: 17295463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Flying under the radar: the new wave of BCR-ABL inhibitors.
    Quintás-Cardama A; Kantarjian H; Cortes J
    Nat Rev Drug Discov; 2007 Oct; 6(10):834-48. PubMed ID: 17853901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural bioinformatics-based prediction of exceptional selectivity of p38 MAP kinase inhibitor PH-797804.
    Xing L; Shieh HS; Selness SR; Devraj RV; Walker JK; Devadas B; Hope HR; Compton RP; Schindler JF; Hirsch JL; Benson AG; Kurumbail RG; Stegeman RA; Williams JM; Broadus RM; Walden Z; Monahan JB
    Biochemistry; 2009 Jul; 48(27):6402-11. PubMed ID: 19496616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of a key element for hydrogen-bonding patterns between protein kinases and their inhibitors.
    Katayama N; Orita M; Yamaguchi T; Hisamichi H; Kuromitsu S; Kurihara H; Sakashita H; Matsumoto Y; Fujita S; Niimi T
    Proteins; 2008 Dec; 73(4):795-801. PubMed ID: 18767165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Roots of imatinib resistance: a question of self-renewal?
    Burchert A
    Drug Resist Updat; 2007; 10(4-5):152-61. PubMed ID: 17683977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. General model for estimation of the inhibition of protein kinases using Monte Carlo simulations.
    Tominaga Y; Jorgensen WL
    J Med Chem; 2004 May; 47(10):2534-49. PubMed ID: 15115396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In silico drug profiling of the human kinome based on a molecular marker for cross reactivity.
    Zhang X; Fernández A
    Mol Pharm; 2008; 5(5):728-38. PubMed ID: 18620417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The interplay of structural information and functional studies in kinase drug design: insights from BCR-Abl.
    Eck MJ; Manley PW
    Curr Opin Cell Biol; 2009 Apr; 21(2):288-95. PubMed ID: 19217274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protein tyrosine kinase-substrate interactions.
    Bose R; Holbert MA; Pickin KA; Cole PA
    Curr Opin Struct Biol; 2006 Dec; 16(6):668-75. PubMed ID: 17085043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of a conserved structural determinant controlling protein kinase sensitivity to selective inhibitors.
    Blencke S; Zech B; Engkvist O; Greff Z; Orfi L; Horváth Z; Kéri G; Ullrich A; Daub H
    Chem Biol; 2004 May; 11(5):691-701. PubMed ID: 15157880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Computational proteomics analysis of binding mechanisms and molecular signatures of the HIV-1 protease drugs.
    Verkhivker G
    Artif Intell Med; 2009; 45(2-3):197-206. PubMed ID: 18926674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.